Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (11263)	11/1/2018 10:22:09 AM
From: mattstat	Read Replies (3) \| Respond to of 12873

It seems like Seymour has become a shareholder advocate. But I also find him being a bit of historical revisionist. It's not like he can shirk all responsibility on Diwan. Sure, Diwan is more than in control NNVC than he should be, but Seymour has to take some responsibility for a stock that collapsed under his reign. I do agree with most of his voting suggestions, nevertheless. I am even voting yes on (iii), because I have a soft spot for him after getting a sense as to how Diwan treated him. (Who knows if that stock ever gets to $2 anyway.)

To: donpat who wrote (11263)	12/5/2018 6:30:51 AM
From: old 'n cranky	Respond to of 12873

We should see the 8k reporting the voting by tomorrow. It will be interesting in light of the recommendations provided here Here are the issues on the table:At this year’s annual meeting you will be asked to: (i) elect two directors and re-elect another director who will each serve for a two year term; (ii) approve our Executive Equity Incentive Plan; (iii) approve the award of warrants to purchase 250,000 shares of common stock in connection with the separation agreement of our former Chief Executive Officer; (iv) approve the award of 525,000 shares of Series A Convertible Preferred Stock to our President in connection with his employment agreement; (v) ratify the selection of our independent registered public accountants; and (vi) transact such other business as may properly come before the annual meeting. The accompanying Notice of Meeting and Proxy Statement describe these matters. We urge you to read this information carefully. (i) OK for the two new directors but NO to the re-election of Stanley Glick (ii) This gives too much leeway to the Board to grant these awards. I’m concerned that they will be awarded without appropriate oversight: NO (iii) This enables me to buy shares at $2/share in three equal tranches starting next January 27th and then again in 2020 and 2021. Obviously I have no comment on this (iv) Should we award Dr. Diwan for not starting toxicology studies, for not selecting a final drug candidate, for not consummating a shingles license agreement and for not scheduling a pre-IND meeting with the FDA. Also, for being the CEO when the stock decreased in value by 70% because none of these promised milestones have been met during this calendar year. NO! (v) and (vi) are OK Eugene Seymour MD MPH